Log in
NASDAQ:INVA

Innoviva Stock Forecast, Price & News

$10.76
-0.09 (-0.83 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$10.61
Now: $10.76
$10.89
50-Day Range
$10.85
MA: $12.28
$13.96
52-Week Range
$7.58
Now: $10.76
$15.62
Volume484,080 shs
Average Volume786,439 shs
Market Capitalization$1.09 billion
P/E Ratio5.22
Dividend YieldN/A
Beta0.9
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Brisbane, California.
Read More
Innoviva logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.87 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INVA
Previous SymbolNASDAQ:THRX
CUSIP88338T10
Phone650-238-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$261.02 million
Cash Flow$1.65 per share
Book Value$3.38 per share

Profitability

Net Income$157.29 million

Miscellaneous

Employees6
Market Cap$1.09 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$10.76
-0.09 (-0.83 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INVA News and Ratings via Email

Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Innoviva (NASDAQ:INVA) Frequently Asked Questions

How has Innoviva's stock been impacted by Coronavirus?

Innoviva's stock was trading at $12.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, INVA shares have decreased by 10.6% and is now trading at $10.76.
View which stocks have been most impacted by COVID-19
.

When is Innoviva's next earnings date?

Innoviva is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Innoviva
.

How were Innoviva's earnings last quarter?

Innoviva Inc (NASDAQ:INVA) announced its quarterly earnings data on Wednesday, July, 29th. The biotechnology company reported $0.69 earnings per share for the quarter, topping analysts' consensus estimates of $0.32 by $0.37. The biotechnology company earned $78.95 million during the quarter. Innoviva had a return on equity of 59.83% and a net margin of 76.28%.
View Innoviva's earnings history
.

Are investors shorting Innoviva?

Innoviva saw a increase in short interest in August. As of August 14th, there was short interest totaling 13,320,000 shares, an increase of 10.3% from the July 30th total of 12,080,000 shares. Based on an average trading volume of 704,700 shares, the short-interest ratio is currently 18.9 days. Approximately 19.3% of the company's stock are short sold.
View Innoviva's Short Interest
.

Who are some of Innoviva's key competitors?

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), Advanced Micro Devices (AMD), NVIDIA (NVDA), Opko Health (OPK) and Sorrento Therapeutics (SRNE).

Who are Innoviva's key executives?

Innoviva's management team includes the following people:
  • Mr. Geoffrey Hulme, Interim Principal Exec. Officer (Age 52)
  • Ms. Marianne Zhen CPA, Chief Accounting Officer (Age 50)
  • Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
  • Dr. Kevin Kwok, Head of Talent Acquisition & Strategy

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Who are Innoviva's major shareholders?

Innoviva's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.73%), LSV Asset Management (3.61%), First Eagle Investment Management LLC (2.03%), Goldman Sachs Group Inc. (1.76%), Man Group plc (1.20%) and Principal Financial Group Inc. (0.55%). Company insiders that own Innoviva stock include Geoffrey Hulme, George Bickerstaff, Innoviva, Inc and Marianne Zhen.
View institutional ownership trends for Innoviva
.

Which major investors are selling Innoviva stock?

INVA stock was sold by a variety of institutional investors in the last quarter, including Atom Investors LP, WINTON GROUP Ltd, Nuveen Asset Management LLC, MERIAN GLOBAL INVESTORS UK Ltd, Man Group plc, State of Tennessee Treasury Department, Nisa Investment Advisors LLC, and Marshall Wace LLP.
View insider buying and selling activity for Innoviva
.

Which major investors are buying Innoviva stock?

INVA stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., First Eagle Investment Management LLC, Jefferies Group LLC, Denali Advisors LLC, Robeco Institutional Asset Management B.V., Canada Pension Plan Investment Board, AJO LP, and TD Asset Management Inc.. Company insiders that have bought Innoviva stock in the last two years include Geoffrey Hulme, George Bickerstaff, and Innoviva, Inc.
View insider buying and selling activity for Innoviva
.

How do I buy shares of Innoviva?

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $10.76.

How big of a company is Innoviva?

Innoviva has a market capitalization of $1.09 billion and generates $261.02 million in revenue each year. The biotechnology company earns $157.29 million in net income (profit) each year or $1.43 on an earnings per share basis. Innoviva employs 6 workers across the globe.

What is Innoviva's official website?

The official website for Innoviva is www.inva.com.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.